Form 8-K - Current report:
SEC Accession No. 0001104659-24-102625
Filing Date
2024-09-25
Accepted
2024-09-25 08:53:01
Documents
16
Period of Report
2024-09-25
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2424686d1_8k.htm   iXBRL 8-K 33363
2 EXHIBIT 3.1 tm2424686d1_ex3-1.htm EX-3.1 765
3 EXHIBIT 99.1 tm2424686d1_ex99-1.htm EX-99.1 8989
7 GRAPHIC tm2424686d1_ex3-1img001.jpg GRAPHIC 595379
  Complete submission text file 0001104659-24-102625.txt   1045323

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA seel-20240925.xsd EX-101.SCH 3015
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE seel-20240925_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE seel-20240925_pre.xml EX-101.PRE 22359
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2424686d1_8k_htm.xml XML 3793
Mailing Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022
Business Address 300 PARK AVENUE 2ND FLOOR NEW YORK NY 10022 (646) 293-2100
SEELOS THERAPEUTICS, INC. (Filer) CIK: 0001017491 (see all company filings)

EIN.: 870449967 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22245 | Film No.: 241321469
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)